Chuyển đến nội dung chính

other

Tesofensine tracker

Educational reference for Tesofensine. Use it inside TrackPep to log doses, side effects, and rotation sites.

Half-life

220 h

Tmax

5 h

Category

other

Also known as: NS2330

Tesofensine is an investigational triple monoamine reuptake inhibitor studied for weight loss. Not FDA-approved. Taken orally.

Mechanism

An investigational small-molecule inhibitor of the reuptake of noradrenaline, dopamine, and serotonin. In research its appetite-suppressant effects are attributed to central monoamine activity.

Research summary

Investigational and not FDA-approved. Originally studied for neurological conditions, it was later evaluated for obesity in phase 2 trials showing weight reduction. Larger confirmatory data and an approved indication are lacking per the literature.

Reported side effects

Reported effects include increased heart rate and blood pressure, dry mouth, insomnia, and mood-related effects, reflecting its monoaminergic activity. The full safety profile is not established given its investigational status.

Educational summary of published research. Not dosing guidance or medical advice.

Sources

  • Tesofensine phase 2 obesity trial (The Lancet) · The Lancet (2008)search PubMed for tesofensine obesity; investigational
  • Monoamine reuptake inhibitor obesity reviews · peer-reviewed review articles (2016)investigational; not FDA-approved

TrackPep là ứng dụng theo dõi. Ứng dụng chỉ ghi lại những gì bạn nhập, không bao giờ đề xuất hay tính toán lượng dùng.